C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Price:
41.88
CNY
-4.67%
Market Closed
Market Cap:
111.9B
CNY
Balance Sheet
Balance Sheet Decomposition
CSPC Innovation Pharmaceutical Co Ltd
CSPC Innovation Pharmaceutical Co Ltd
| Current Assets | 2.4B |
| Cash & Short-Term Investments | 1.3B |
| Receivables | 578.9m |
| Other Current Assets | 481.6m |
| Non-Current Assets | 3.4B |
| Long-Term Investments | 264.2m |
| PP&E | 2.5B |
| Intangibles | 226.8m |
| Other Non-Current Assets | 401m |
Balance Sheet
CSPC Innovation Pharmaceutical Co Ltd
CSPC Innovation Pharmaceutical Co Ltd
Currency: CNY
Millions
Annual
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
151
|
68
|
156
|
473
|
1 138
|
1 232
|
2 192
|
3 422
|
859
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
1 232
|
2 192
|
3 422
|
859
|
|
| Cash Equivalents |
151
|
68
|
156
|
473
|
1 138
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
960
|
322
|
414
|
0
|
0
|
826
|
|
| Total Receivables |
172
|
272
|
349
|
365
|
329
|
434
|
732
|
581
|
661
|
|
| Accounts Receivables |
108
|
125
|
189
|
173
|
146
|
270
|
481
|
404
|
314
|
|
| Other Receivables |
64
|
146
|
160
|
192
|
182
|
164
|
250
|
176
|
347
|
|
| Inventory |
67
|
114
|
129
|
124
|
111
|
217
|
238
|
225
|
399
|
|
| Other Current Assets |
4
|
13
|
27
|
15
|
14
|
22
|
29
|
42
|
58
|
|
| Total Current Assets |
393
|
466
|
661
|
1 937
|
1 913
|
2 318
|
3 191
|
4 618
|
2 802
|
|
| PP&E Net |
509
|
594
|
655
|
685
|
737
|
610
|
1 071
|
2 339
|
2 708
|
|
| PP&E Gross |
509
|
594
|
655
|
685
|
737
|
610
|
1 071
|
2 339
|
2 708
|
|
| Accumulated Depreciation |
167
|
193
|
233
|
259
|
301
|
329
|
551
|
715
|
915
|
|
| Intangible Assets |
65
|
62
|
60
|
58
|
55
|
42
|
50
|
232
|
225
|
|
| Goodwill |
0
|
0
|
4
|
4
|
4
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
156
|
236
|
243
|
253
|
267
|
264
|
|
| Other Long-Term Assets |
2
|
7
|
12
|
13
|
10
|
12
|
19
|
17
|
22
|
|
| Other Assets |
0
|
0
|
4
|
4
|
4
|
0
|
0
|
0
|
0
|
|
| Total Assets |
969
N/A
|
1 129
+17%
|
1 391
+23%
|
2 852
+105%
|
2 955
+4%
|
3 226
+9%
|
4 584
+42%
|
7 472
+63%
|
6 022
-19%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
72
|
58
|
64
|
80
|
59
|
69
|
159
|
1 264
|
303
|
|
| Accrued Liabilities |
7
|
7
|
18
|
16
|
21
|
24
|
70
|
68
|
66
|
|
| Short-Term Debt |
0
|
46
|
33
|
13
|
5
|
0
|
30
|
10
|
103
|
|
| Current Portion of Long-Term Debt |
120
|
0
|
50
|
0
|
0
|
1
|
0
|
1
|
1
|
|
| Other Current Liabilities |
161
|
164
|
185
|
293
|
150
|
137
|
325
|
561
|
961
|
|
| Total Current Liabilities |
360
|
275
|
349
|
401
|
234
|
231
|
583
|
1 904
|
1 434
|
|
| Long-Term Debt |
0
|
50
|
0
|
0
|
0
|
0
|
20
|
1
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
1
|
|
| Minority Interest |
0
|
0
|
9
|
9
|
9
|
8
|
9
|
202
|
765
|
|
| Other Liabilities |
37
|
38
|
42
|
36
|
33
|
34
|
37
|
84
|
90
|
|
| Total Liabilities |
397
N/A
|
362
-9%
|
400
+10%
|
446
+12%
|
277
-38%
|
274
-1%
|
648
+137%
|
2 191
+238%
|
2 292
+5%
|
|
| Equity | ||||||||||
| Common Stock |
150
|
150
|
150
|
200
|
420
|
546
|
619
|
1 171
|
1 405
|
|
| Retained Earnings |
412
|
607
|
831
|
1 104
|
1 376
|
1 651
|
2 177
|
1 988
|
1 667
|
|
| Additional Paid In Capital |
10
|
10
|
10
|
1 102
|
882
|
756
|
1 138
|
2 125
|
977
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
321
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
|
| Total Equity |
572
N/A
|
767
+34%
|
991
+29%
|
2 406
+143%
|
2 678
+11%
|
2 952
+10%
|
3 936
+33%
|
5 281
+34%
|
3 731
-29%
|
|
| Total Liabilities & Equity |
969
N/A
|
1 129
+17%
|
1 391
+23%
|
2 852
+105%
|
2 955
+4%
|
3 226
+9%
|
4 584
+42%
|
7 472
+63%
|
6 022
-19%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
410
|
410
|
410
|
546
|
546
|
1 179
|
1 337
|
1 405
|
1 405
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
